# OnCo record mds-higher-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mds-higher-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mds-higher-risk" ;
  schema:name "Higher-risk myelodysplastic syndromes"@en ;
  schema:alternateName "High-risk MDS"@en, "IPSS-R high and very high MDS"@en, "MDS with increased blasts"@en, "Higher-risk myelodysplastic neoplasms"@en ;
  schema:description "Higher-risk myelodysplastic syndromes behave like a slow leukaemia and often become one. Azacitidine lengthens life and a donor stem cell transplant is the only cure; every attempt to improve on azacitidine in a large trial, including the venetoclax combination tested in VERONA, has so far failed."@en ;
  schema:url <https://onco.cc/cancers/mds-higher-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Myelodysplastic_syndrome> ;
  schema:citation <https://en.wikipedia.org/wiki/Myelodysplastic_syndrome>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cd47-blockade/>, <https://onco.cc/technologies/tim3-blockade/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/tim3/> ;
  onco:terms <https://onco.cc/terms/hma/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/staging-systems/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/terms/conditioning-regimen/> ;
  onco:pipeline <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/tuspetinib/>, <https://onco.cc/trials/nct05732103/>, <https://onco.cc/trials/nct07216443/>, <https://onco.cc/drugs/tregzi/> ;
  onco:standardOfCare <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/terms/conditioning-regimen/>, <https://onco.cc/trials/nct07216443/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/terms/hma/>, <https://onco.cc/trials/nct05883956/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/trials/nct05732103/> .